Corticorelin API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Corticorelin API 86784-80-7?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Corticorelin. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Corticorelin
- Synonyms:
- Corticoliberin human , Corticorelin (human) , Corticotropin releasing hormone human , Corticotropin-releasing factor , Corticotropin-releasing factor (human) , Corticotropin-releasing hormone , CRF , hCRF , Human corticoliberin , Human corticotropin-releasing factor
- Cas Number:
- 86784-80-7
- DrugBank number:
- DB05394
- Unique Ingredient Identifier:
- 305OE8862Y
General Description:
Corticorelin, identified by CAS number 86784-80-7, is a notable compound with significant therapeutic applications. Corticotropin-releasing factor is studied in the treatment of brain cancer. It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory. Human corticotropin-releasing factor may help reduce symptoms caused by edema (swelling) of the brain. It is a type of neurohormone, also called hCRF.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in brain cancer and neurologic disorders. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Corticorelin functions by: Corticotropin-releasing factor is produced by neuroendocrine cells in the paraventricular nucleus of the hypothalamus and is released from neurosecretory terminals of these neurons into the primary capillary plexus of the hypothalamo-hypophyseal portal system. The portal system carries the Corticotropin-releasing hormone(CRH) to the anterior lobe of the pituitary where it stimulates the secretion of corticotropin (ACTH) and other biologically active substances. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Categories:
Corticorelin is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Corticotropin-Releasing Hormone, Diagnostic Agents, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypothalamic Hormones, Nerve Tissue Proteins, Neuropeptides, Peptide Hormones, Peptides, Pituitary Hormone-Releasing Hormones, Proteins, Tests for Pituitary Function. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Corticorelin is a type of Hormonal Agents
Hormonal agents are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the medical field. These substances play a crucial role in regulating and modulating hormonal functions within the body. Hormonal agents are designed to mimic or manipulate the effects of naturally occurring hormones, allowing healthcare professionals to treat various endocrine disorders and hormonal imbalances.
Hormonal agents are commonly employed in the treatment of conditions such as hypothyroidism, hyperthyroidism, diabetes, and hormonal cancers. These APIs work by interacting with specific hormone receptors, either by stimulating or inhibiting their activity, to restore the balance of hormones in the body. They can be administered orally, intravenously, or through other routes depending on the specific medication and patient needs.
Pharmaceutical companies employ rigorous manufacturing processes and quality control measures to ensure the purity, potency, and safety of hormonal agent APIs. These APIs are synthesized using chemical or biotechnological methods, often starting from natural hormone sources or through recombinant DNA technology. Stringent regulatory guidelines are in place to guarantee the efficacy and safety of hormonal agent APIs, ensuring that patients receive high-quality medications.
As the demand for hormone-related therapies continues to grow, ongoing research and development efforts focus on enhancing the effectiveness and reducing the side effects of hormonal agent APIs. This includes the exploration of novel delivery systems, advanced formulations, and targeted drug delivery methods. By continuously advancing our understanding and capabilities in hormonal agents, the medical community can improve patient outcomes and quality of life for individuals with hormonal disorders.
